In this study TCF3::PBX1-positive ALL showed better DFS than KMT2A::AFF1- and BCR::ABL1p190−positive ALL, suggesting that the current treatment protocols used in Mexico show improvements in early mortality. This evidence concerns the gene TCF3 and acute lymphoblastic leukemia.